BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20832405)

  • 21. An efficient synthesis of dopamine transporter tracer [¹⁸F]FECNT.
    Murali D; Barnhart TE; Vandehey NT; Christian BT; Nickles RJ; Converse AK; Larson JA; Holden JE; Schneider ML; Dejesus OT
    Appl Radiat Isot; 2013 Feb; 72():128-32. PubMed ID: 23208243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.
    Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW
    J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
    Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
    J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.
    Stehouwer JS; Daniel LM; Chen P; Voll RJ; Williams L; Plott SJ; Votaw JR; Owens MJ; Howell L; Goodman MM
    J Med Chem; 2010 Aug; 53(15):5549-57. PubMed ID: 20597489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
    J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
    Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
    Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
    Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A one-step automated synthesis of the dopamine transporter ligand [(18)F]FECNT from the chlorinated precursor.
    Pijarowska-Kruszyna J; Jaron A; Kachniarz A; Malkowski B; Garnuszek P; Mikolajczak R
    J Labelled Comp Radiopharm; 2016 Mar; 59(3):82-6. PubMed ID: 26853227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques.
    Shimony JS; Rutlin J; Karimi M; Tian L; Snyder AZ; Loftin SK; Norris SA; Perlmutter JS
    PLoS One; 2018; 13(9):e0202201. PubMed ID: 30183721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Difficulties in dopamine transporter radioligand PET analysis: the example of LBT-999 using [18F] and [11C] labelling Part I: PET studies.
    Saba W; Peyronneau MA; Dollé F; Goutal S; Bottlaender M; Valette H
    Nucl Med Biol; 2012 Feb; 39(2):227-33. PubMed ID: 22033025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography.
    Xing D; Chen P; Keil R; Kilts CD; Shi B; Camp VM; Malveaux G; Ely T; Owens MJ; Votaw J; Davis M; Hoffman JM; BaKay RA; Subramanian T; Watts RL; Goodman MM
    J Med Chem; 2000 Feb; 43(4):639-48. PubMed ID: 10691690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques.
    Brown CA; Karimi MK; Tian L; Flores H; Su Y; Tabbal SD; Loftin SK; Moerlein SM; Perlmutter JS
    Ann Neurol; 2013 Oct; 74(4):602-10. PubMed ID: 23686841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 2beta-carbomethoxy-3beta-(4-[18F]fluorophenyl)tropane and N-(3-[18F]fluoropropyl)-2beta-carbomethoxy-3beta-(4-fluorophenyl)nortropane, tracers for imaging dopamine transporter in rat.
    Marjamäki P; Haaparanta M; Forsback S; Fagerholm V; Eskola O; Grönroos T; Koivula T; Solin O
    Mol Imaging Biol; 2010 Jun; 12(3):269-77. PubMed ID: 19949983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography.
    Nagai Y; Obayashi S; Ando K; Inaji M; Maeda J; Okauchi T; Ito H; Suhara T
    Synapse; 2007 Oct; 61(10):809-19. PubMed ID: 17598150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
    Chalon S; Hall H; Saba W; Garreau L; Dollé F; Halldin C; Emond P; Bottlaender M; Deloye JB; Helfenbein J; Madelmont JC; Bodard S; Mincheva Z; Besnard JC; Guilloteau D
    J Pharmacol Exp Ther; 2006 Apr; 317(1):147-52. PubMed ID: 16339913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys.
    Wilcox KM; Lindsey KP; Votaw JR; Goodman MM; Martarello L; Carroll FI; Howell LL
    Synapse; 2002 Jan; 43(1):78-85. PubMed ID: 11746736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of isoflurane with the dopamine transporter.
    Votaw J; Byas-Smith M; Hua J; Voll R; Martarello L; Levey AI; Bowman FD; Goodman M
    Anesthesiology; 2003 Feb; 98(2):404-11. PubMed ID: 12552200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.